Adial Pharmaceuticals, Inc - Common Stock (ADIL)

The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.

Adial secures USPTO patent for AD04, expanding coverage to treat alcohol and opioid-related disorders in patients with genetic markers.

Adial Pharmaceuticals secured FDA support for its AD04 bridging strategy, paving the way for Phase 3 trials in 2025 after confirming bioequivalence.

Adial Pharmaceuticals received a U.S. patent for genetic marker-based treatment methods and completed a pharmacokinetics study supporting its Phase 3 trial.

Adial Pharmaceuticals announced completion of PK study for AD04, confirming predictable bioavailability, dose proportionality, and no food effect.

Adial Pharmaceuticals expands its IP with a U.S. patent for targeted AUD treatment using AD04, supporting its personalized medicine strategy.

Adial Pharmaceuticals completes PK study for AD04 in AUD, meeting FDA requirements and preparing for Phase 3 trial. Data supports 505(b)(2) application.

Adial Pharmaceuticals secures a new patent allowance for AD04, enhancing its precision medicine approach for treating alcohol use disorder. Topline results from AD04's latest study are expected in Q4 2024.

Adial Pharmaceuticals just reported results for the second quarter of 2024.

Adial Pharmaceuticals has partnered with Boudicca Dx to advance the regulatory and technical strategy for its companion diagnostic test for AD0 for Alcohol Use Disorder. This collaboration is pivotal for Adial's upcoming Phase 3 trial.

Adial Pharmaceuticals announces the completion of the pharmacokinetics study dosing for AD04, their lead investigational treatment for Alcohol Use Disorder in heavy drinking patients. Topline results expected in Q4 2024 will inform Phase 3 clinical trial plans.

Serve Robotics stock is down on Tuesday after the company revealed the pricing of warrants for SERV shares in a private placement.

Jaguar Health stock is down on Tuesday as JAGX investors react to failed results from a Phase 3 clinical trial of crofelemer.

Adial Pharmaceuticals stock is up with heavy trading of ADIL after providing investors with an update on its AD04 clinical trial.

Adial Pharmaceuticals progresses to the second cohort in the AD04 pharmacokinetics study for Alcohol Use Disorder. This study, involving up to 30 healthy volunteers, will provide critical insights for the upcoming Phase 3 trial. Topline results expected Q4 2024.

ADIL stock results show that Adial Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023.